M&A Deal Summary |
|
---|---|
Date | 2019-01-07 |
Target | Loxo Oncology |
Sector | Life Science |
Buyer(s) | Lilly |
Deal Type | Add-on Acquisition |
Deal Value | 8.0B USD |
Advisor(s) | Goldman Sachs (Financial) Fenwick & West (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1876 |
Sector | Life Science |
Employees | 43,000 |
Revenue | 34.1B USD (2023) |
Lilly discovers, develops, manufactures, and markets products in two business segments—human pharmaceutical products and animal health products. The mission of its human pharmaceutical business is to make medicines that help people live longer, healthier, more active lives. Most of the products Eli Lilly sells were discovered or developed by its own scientists, and the Company's success depends to a great extent on its ability to continue to discover, develop, and bring to market innovative new medicines. Eli Lilly's animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. Eli Lilly manufactures and distributes its products through facilities in the US, Puerto Rico, and 11 other countries. Lilly was founded in 1876 and is based in Indianapolis, Indiana.
DEAL STATS | # |
---|---|
Overall | 23 of 34 |
Sector (Life Science) | 16 of 27 |
Type (Add-on Acquisition) | 17 of 27 |
State (Connecticut) | 1 of 1 |
Country (United States) | 19 of 29 |
Year (2019) | 1 of 1 |
Size (of disclosed) | 1 of 20 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2018-12-14 |
Hydra Biosciences - Pre-Clinical Pain Program
Cambridge, Massachusetts, United States Hydra Biosciences, Inc. - Pre-Clinical Pain Program of TRPA1 antagonists, part of the Transient Receptor Potential (TRP) family of ion channels, that is currently being studied for the potential treatment of chronic pain syndromes. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2019-04-22 |
Eli Lilly - Antibiotics Brands & Manufacturing Facility
Indianapolis, Indiana, United States Eli Lilly and Co. - Antibiotics Brands & Manufacturing Facility comprises Ceclor and Vancocin, as well as a manufacturing facility in Suzhou, China that produces Ceclor. |
Sell | $375M |